Observational studyJournal of neurointerventional surgery2026
Initial experience with the antithrombogenic-coated CARESTO stent for acute symptomatic cervical internal carotid artery dissections: multicenter study.
Observational study in Journal of neurointerventional surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the technical feasibility, safety, and short-term to mid-term efficacy of the antithrombogenic-coated CARESTO stent in the endovascular treatment of acute symptomatic cervical internal carotid artery dissections (CICAD) with hemodynamically relevant stenosis and disabling neurological deficits.
methodsThis retrospective multicenter study evaluated patients with acute symptomatic CICAD who underwent endovascular treatment with the CARESTO stent. Clinical endpoints included changes in the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) scores. Imaging endpoints assessed vessel patency, arterial diameter improvement, and revascularization success, defined as a modified Thrombolysis in Cerebral Infarction (mTICI) score ≥2b. Safety was evaluated by documenting periprocedural complications.
resultsBetween January 2023 and May 2025, 31 patients were treated across six participating neurovascular centers. The mean age was 52.3±10.2 years; 54.8% were female. Stent deployment was successful in all cases. In those with intracranial vessel occlusion (n=22), recanalization was achieved in all patients (mTICI 3: 61.3%; mTICI 2c: 22.6%; mTICI 2b: 16.1%). ICA diameter improved from 1.0±0.5 mm to 4.6±0.6 mm. Median NIHSS score decreased from 11 (IQR 8-14.5) to 1 (IQR 1-3) at 3 months; mRS≤2 was achieved in 83.9%. All stents remained patent, with no major complications or deaths.
conclusionThis initial multicenter experience suggests that the CARESTO stent is technically feasible and may offer a safe and effective treatment option for acute CICAD. These findings support further prospective evaluation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.